Race for new IPF treatment: can experimental drug slow deadly lung scarring?

NCT ID NCT06317285

Terminated Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

Summary

This study tested a new drug, GSK3915393, to see if it could slow the progression of idiopathic pulmonary fibrosis (IPF), a serious disease that causes permanent lung scarring and makes breathing difficult. About 158 people with IPF were randomly assigned to receive either the new drug or a placebo for 26 weeks. The main goal was to see if the drug could help preserve lung function, measured by a breathing test, and to check for side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Newport Beach, California, 92663, United States
GSK Investigational Site

Jacksonville, Florida, 32224, United States
GSK Investigational Site

St. Petersburg, Florida, 33704, United States
GSK Investigational Site

Ann Arbor, Michigan, 48109-5360, United States
GSK Investigational Site

Rochester, Minnesota, 55905, United States
GSK Investigational Site

New York, New York, 10065, United States
GSK Investigational Site

Wilmington, North Carolina, 28401, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19140, United States
GSK Investigational Site

Nashville, Tennessee, 37204, United States
GSK Investigational Site

Cypress, Texas, 77429, United States
GSK Investigational Site

Buenos Aires, C1426ABP, Argentina
GSK Investigational Site

Ciudad Autonoma de Bueno, C1207AAP, Argentina
GSK Investigational Site

Florida, B1602DQD, Argentina
GSK Investigational Site

La Plata, 1900, Argentina
GSK Investigational Site

Mendoza, M5500CCG, Argentina
GSK Investigational Site

Rosario, S2000DBS, Argentina
GSK Investigational Site

Vancouver, British Columbia, V5Z 1M9, Canada
GSK Investigational Site

St. John's, Newfoundland and Labrador, A1B 3V6, Canada
GSK Investigational Site

Ajax, Ontario, L1S 2J5, Canada
GSK Investigational Site

Hamilton, Ontario, L8N 4A6, Canada
GSK Investigational Site

Trois-Rivières, Quebec, G8T 7A1, Canada
GSK Investigational Site

La Tronche, 38700, France
GSK Investigational Site

Paris, 75018, France
GSK Investigational Site

Pessac, 33604, France
GSK Investigational Site

Rennes, 35000, France
GSK Investigational Site

Rouen, 76000, France
GSK Investigational Site

Toulouse, 31059, France
GSK Investigational Site

Essen, 45293, Germany
GSK Investigational Site

Hanover, 30173, Germany
GSK Investigational Site

Heidelberg, 69126, Germany
GSK Investigational Site

Wuppertal, 42283, Germany
GSK Investigational Site

Catania, 95123, Italy
GSK Investigational Site

Monza MB, 20900, Italy
GSK Investigational Site

Naples, Italy
GSK Investigational Site

Padua, 35128, Italy
GSK Investigational Site

Perugia, 06132, Italy
GSK Investigational Site

Pisa, 56124, Italy
GSK Investigational Site

Roma, 00168, Italy
GSK Investigational Site

Sassari, 07100, Italy
GSK Investigational Site

Torrette AN, Italy
GSK Investigational Site

Eindhoven, 5623 EJ, Netherlands
GSK Investigational Site

Rotterdam, 3015 CE, Netherlands
GSK Investigational Site

Bialystok, 15-044, Poland
GSK Investigational Site

Lodz, 90-153, Poland
GSK Investigational Site

Poznan, 60-569, Poland
GSK Investigational Site

Barcelona, 08907, Spain
GSK Investigational Site

Barcelona, Spain
GSK Investigational Site

Madrid, 28006, Spain
GSK Investigational Site

Madrid, 28007, Spain
GSK Investigational Site

Oviedo, 33011, Spain
GSK Investigational Site

Pozuelo de AlarcOn Madr, 28223, Spain
GSK Investigational Site

Santander, 39011, Spain
GSK Investigational Site

Seville, 41013, Spain
GSK Investigational Site

Edinburgh, EH16 4SA, United Kingdom
GSK Investigational Site

Leeds West Yorkshire, LS9 7TF, United Kingdom
GSK Investigational Site

London, SW3 6HP, United Kingdom

Conditions

Explore the condition pages connected to this study.

IDIOPATHIC PULMONARY FIBROSIS